Natera, Inc. (NTRA) 10-Year Financial Performance & Capital Metrics

NTRA • • Industrial / General

HealthcareDiagnostics & ResearchMolecular Diagnostics & Genetic TestingReproductive & Prenatal Genetics

AboutNatera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.Show more

Revenue $1.7B +56.7%
EBITDA -$191M +53.1%
Net Income -$190M +56.2%
EPS (Diluted) -1.53 +59.5%
Gross Margin 60.3% +32.5%
EBITDA Margin -11.28% +70.1%
Operating Margin -13.1% +68.2%
Net Margin -11.22% +72.1%
ROE -19.42% +67.1%
ROIC -33.27% +37.8%
Debt/Equity 0.16 -72.9%
Interest Coverage -20.80 +41.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 82 (top 18%)
✓Strong 5Y sales CAGR of 41.2%
✓Efficient asset utilization: 1.0x turnover

✗Weaknesses

✗Expensive at 25.1x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y26.69%

5Y41.2%

3Y39.47%

TTM38.17%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-44.02%

EPS CAGR

10Y-

5Y-

3Y-

TTM-29.38%

ROCE

10Y Avg-55.78%

5Y Avg-40.29%

3Y Avg-36.62%

Latest-18.14%

Peer Comparison

Reproductive & Prenatal Genetics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
SERASera Prognostics, Inc.	132.45M	3.52	-3.56	-74.84%	-343.43%	-39.7%		0.02
NTRANatera, Inc.	33.52B	240.34	-157.09	56.75%	-14.61%	-24.69%	0.21%	0.16

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	190.35M	217.07M	210.94M	257.65M	302.33M	391M	625.49M	820.22M	1.08B	1.7B
Revenue Growth %	0.2%	0.14%	-0.03%	0.22%	0.17%	0.29%	0.6%	0.31%	0.32%	0.57%
Cost of Goods Sold+	112.84M	135.57M	139.6M	166.06M	175.47M	203.62M	318.42M	456.26M	589.83M	673.75M
COGS % of Revenue	0.59%	0.62%	0.66%	0.64%	0.58%	0.52%	0.51%	0.56%	0.54%	0.4%
Gross Profit+	77.51M	81.5M	71.34M	91.6M	126.86M	187.38M	307.07M	363.97M	492.74M	1.02B
Gross Margin %	0.41%	0.38%	0.34%	0.36%	0.42%	0.48%	0.49%	0.44%	0.46%	0.6%
Gross Profit Growth %	-0.04%	0.05%	-0.12%	0.28%	0.38%	0.48%	0.64%	0.19%	0.35%	1.08%
Operating Expenses+	137.35M	177.99M	205.37M	206.23M	243.15M	403.66M	775.24M	905.01M	938.99M	1.25B
OpEx % of Revenue	0.72%	0.82%	0.97%	0.8%	0.8%	1.03%	1.24%	1.1%	0.87%	0.73%
Selling, General & Admin	109.64M	136.13M	155.31M	154.87M	206.18M	303.63M	511.03M	588.59M	618.31M	841.31M
SG&A % of Revenue	0.58%	0.63%	0.74%	0.6%	0.68%	0.78%	0.82%	0.72%	0.57%	0.5%
Research & Development	27.71M	41.86M	50.06M	51.35M	51.36M	100.03M	264.21M	316.42M	320.68M	404.14M
R&D % of Revenue	0.15%	0.19%	0.24%	0.2%	0.17%	0.26%	0.42%	0.39%	0.3%	0.24%
Other Operating Expenses	0	0	0	0	-14.39M	0	0	0	0	0
Operating Income+	-59.84M	-96.49M	-134.03M	-114.63M	-116.29M	-216.28M	-468.17M	-541.04M	-446.25M	-222.29M
Operating Margin %	-0.31%	-0.44%	-0.64%	-0.44%	-0.38%	-0.55%	-0.75%	-0.66%	-0.41%	-0.13%
Operating Income Growth %	-90.98%	-0.61%	-0.39%	0.14%	-0.01%	-0.86%	-1.16%	-0.16%	0.18%	0.5%
EBITDA+	-54.3M	-90.31M	-126.88M	-107.13M	-108.56M	-207.66M	-456.92M	-510.57M	-407.63M	-191.33M
EBITDA Margin %	-0.29%	-0.42%	-0.6%	-0.42%	-0.36%	-0.53%	-0.73%	-0.62%	-0.38%	-0.11%
EBITDA Growth %	-10.34%	-0.66%	-0.4%	0.16%	-0.01%	-0.91%	-1.2%	-0.12%	0.2%	0.53%
D&A (Non-Cash Add-back)	5.54M	6.18M	7.14M	7.5M	7.73M	8.61M	11.25M	30.47M	38.62M	30.97M
EBIT	-66.77M	-99.65M	-132.96M	-114.63M	-112.14M	-214.56M	-462.79M	-537.5M	-421.89M	-179.05M
Net Interest Income+	-2.54M	865K	-1.83M	-13.21M	-6.54M	-7.52M	-2.92M	-5.78M	11.71M	32.56M
Interest Income	964K	1.4M	2.38M	0	4.15M	7.56M	5.38M	3.54M	24.35M	43.25M
Interest Expense	3.5M	533K	4.21M	10.48M	10.69M	15.08M	8.3M	9.32M	12.64M	10.69M
Other Income/Expense	-10.44M	865K	-1.83M	-13.21M	-6.54M	-13.37M	-2.92M	-5.78M	11.71M	32.56M
Pretax Income+	-70.28M	-95.62M	-135.86M	-127.83M	-122.83M	-229.65M	-471.1M	-546.82M	-434.53M	-189.73M
Pretax Margin %	-0.37%	-0.44%	-0.64%	-0.5%	-0.41%	-0.59%	-0.75%	-0.67%	-0.4%	-0.11%
Income Tax+	0	142K	454K	321K	2M	98K	618K	978K	271K	695K
Effective Tax Rate %	1%	1%	1%	1%	1.02%	1%	1%	1%	1%	1%
Net Income+	-70.28M	-95.77M	-136.31M	-128.15M	-124.83M	-229.74M	-471.72M	-547.8M	-434.8M	-190.43M
Net Margin %	-0.37%	-0.44%	-0.65%	-0.5%	-0.41%	-0.59%	-0.75%	-0.67%	-0.4%	-0.11%
Net Income Growth %	-12.64%	-0.36%	-0.42%	0.06%	0.03%	-0.84%	-1.05%	-0.16%	0.21%	0.56%
Net Income (Continuing)	-70.28M	-95.77M	-137.63M	-128.15M	-124.83M	-229.74M	-471.72M	-547.8M	-434.8M	-190.43M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.47	-1.86	-2.54	-2.22	-1.79	-2.84	-5.21	-5.57	-3.78	-1.53
EPS Growth %	-9.5%	-0.27%	-0.37%	0.13%	0.19%	-0.59%	-0.83%	-0.07%	0.32%	0.6%
EPS (Basic)	-1.47	-1.86	-2.56	-2.22	-1.79	-2.84	-5.21	-5.57	-3.78	-1.53
Diluted Shares Outstanding	47.69M	51.58M	53.6M	57.85M	69.56M	81.01M	90.56M	98.41M	115M	124.72M
Basic Shares Outstanding	47.65M	51.45M	53.31M	57.73M	69.56M	81.01M	90.56M	98.41M	115M	124.72M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	250.73M	174.12M	180.63M	240.52M	523.17M	862.66M	1.09B	1.21B	1.26B	1.38B
Cash & Short-Term Investments	230.53M	146.12M	118.87M	153.87M	440.99M	737.27M	914.28M	898.39M	878.98M	968.28M
Cash Only	28.95M	15.26M	12.62M	46.41M	61.93M	48.67M	84.39M	466.09M	642.1M	945.59M
Short-Term Investments	201.59M	130.86M	106.25M	107.46M	379.06M	688.61M	829.9M	432.3M	236.88M	22.69M
Accounts Receivable	5.86M	13.4M	44.09M	62.22M	53.35M	78.56M	122.07M	244.38M	278.29M	314.17M
Days Sales Outstanding	11.24	22.52	76.29	88.15	64.41	73.34	71.24	108.75	93.83	67.58
Inventory	8.09M	6.41M	9M	13.63M	12.39M	20.03M	26.91M	35.41M	40.76M	44.74M
Days Inventory Outstanding	26.18	17.27	23.53	29.97	25.78	35.91	30.85	28.32	25.22	24.24
Other Current Assets	901K	1.09M	59K	4.6M	55K	187K	228K	33.63M	60.52M	48.63M
Total Non-Current Assets+	14.51M	36.56M	33.99M	27.65M	59.49M	69.49M	143.35M	182.66M	183.15M	284.92M
Property, Plant & Equipment	12.71M	32.29M	29.67M	24.34M	47.01M	54.75M	124.53M	164.33M	167.75M	248.19M
Fixed Asset Turnover	14.98x	6.72x	7.11x	10.59x	6.43x	7.14x	5.02x	4.99x	6.45x	6.84x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	1.8M	4.28M	4.32M	3.32M	12.48M	14.74M	18.82M	18.33M	15.4M	36.72M
Total Assets+	265.24M	210.68M	214.61M	268.17M	582.66M	932.15M	1.24B	1.39B	1.44B	1.66B
Asset Turnover	0.72x	1.03x	0.98x	0.96x	0.52x	0.42x	0.51x	0.59x	0.75x	1.02x
Asset Growth %	1.15%	-0.21%	0.02%	0.25%	1.17%	0.6%	0.33%	0.13%	0.03%	0.15%
Total Current Liabilities+	80.47M	96.42M	105.56M	113.98M	179.87M	199.05M	218.96M	310.5M	307.27M	344.05M
Accounts Payable	7.33M	11.48M	8.53M	14.59M	8.6M	8.1M	27.21M	31.15M	15M	34.92M
Days Payables Outstanding	23.72	30.9	22.3	32.06	17.9	14.51	31.19	24.92	9.28	18.92
Short-Term Debt	42.09M	49.62M	50.11M	50.15M	50.12M	50.05M	50.05M	80.35M	80.4M	80.36M
Deferred Revenue (Current)	144K	574K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	12.24M	22.39M	19.04M	22.68M	25.5M	47.74M	58.15M	62.96M	69.1M	73.39M
Current Ratio	3.12x	1.81x	1.71x	2.11x	2.91x	4.33x	4.99x	3.90x	4.10x	4.00x
Quick Ratio	3.02x	1.74x	1.63x	1.99x	2.84x	4.23x	4.87x	3.79x	3.96x	3.87x
Cash Conversion Cycle	13.7	8.89	77.52	86.05	72.29	94.73	70.9	112.16	109.77	72.9
Total Non-Current Liabilities+	0	7.79M	83.64M	122.03M	124.07M	246.86M	364.23M	378.23M	369.1M	121.27M
Long-Term Debt	0	0	73.06M	73.36M	73.66M	202.49M	280.39M	281.65M	282.94M	0
Capital Lease Obligations	0	0	0	0	26.3M	21.25M	61.04M	76.58M	67.03M	96.59M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	7.79M	10.57M	8.61M	310K	320K	1.48M	0	0	0
Total Liabilities	80.47M	104.2M	189.2M	236.01M	303.94M	445.92M	583.18M	688.73M	676.37M	465.31M
Total Debt+	42.09M	49.62M	123.18M	123.51M	155.81M	281.09M	397.23M	446.22M	441.99M	187.12M
Net Debt	13.14M	34.37M	110.56M	77.1M	93.89M	232.43M	312.85M	-19.87M	-200.1M	-758.47M
Debt / Equity	0.23x	0.47x	4.85x	3.84x	0.56x	0.58x	0.61x	0.63x	0.58x	0.16x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-17.07x	-181.03x	-31.81x	-10.94x	-10.88x	-14.34x	-56.37x	-58.06x	-35.31x	-20.80x
Total Equity+	184.76M	106.48M	25.42M	32.16M	278.71M	486.24M	653.3M	705.74M	765.33M	1.2B
Equity Growth %	2.08%	-0.42%	-0.76%	0.27%	7.67%	0.74%	0.34%	0.08%	0.08%	0.56%
Book Value per Share	3.87	2.06	0.47	0.56	4.01	6.00	7.21	7.17	6.66	9.58
Total Shareholders' Equity	184.76M	106.48M	25.42M	32.16M	278.71M	486.24M	653.3M	705.74M	765.33M	1.2B
Common Stock	5K	5K	6K	7K	8K	9K	10K	11K	11K	12K
Retained Earnings	-250.08M	-345.85M	-446.38M	-574.53M	-699.17M	-929.32M	-1.39B	-1.94B	-2.38B	-2.57B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.42M	-725K	-766K	-552K	919K	4.26M	-2.29M	-16.36M	-3.08M	-344K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-37.83M	-74.05M	-97.83M	-70.58M	-63.44M	-182.51M	-335.24M	-431.5M	-246.96M	135.66M
Operating CF Margin %	-0.2%	-0.34%	-0.46%	-0.27%	-0.21%	-0.47%	-0.54%	-0.53%	-0.23%	0.08%
Operating CF Growth %	-4.61%	-0.96%	-0.32%	0.28%	0.1%	-1.88%	-0.84%	-0.29%	0.43%	1.55%
Net Income	-70.28M	-100.33M	-137.63M	-128.15M	-124.83M	-229.74M	-471.72M	-547.8M	-434.8M	-190.43M
Depreciation & Amortization	5.54M	6.18M	7.14M	7.5M	7.73M	8.61M	11.25M	16.7M	24.1M	30.97M
Stock-Based Compensation	7.33M	10.6M	11.4M	14.2M	28.62M	50.17M	115.22M	152.38M	191.81M	274.43M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	10.23M	7.16M	1.65M	8.72M	-2.17M	27.58M	55.61M	30.36M	19.89M	18.55M
Working Capital Changes	9.35M	2.34M	19.61M	27.16M	27.2M	-39.13M	-45.6M	-83.15M	-47.95M	2.14M
Change in Receivables	-450K	-3.96M	6.32M	-18.09M	2.42M	-25.83M	-43.51M	-122.31M	-33.9M	-35.88M
Change in Inventory	2.93M	-431K	-3.09M	-4.9M	917K	-7.47M	-6.88M	-8.5M	-5.35M	-3.98M
Change in Payables	1.35M	1.26M	217K	3.78M	-6.26M	-118K	19.22M	5.46M	-15.46M	13.21M
Cash from Investing+	-210.68M	47.03M	13.78M	-5.16M	-266.35M	-331.46M	-205.19M	330.34M	168.5M	137.62M
Capital Expenditures	-7.85M	-23.14M	-9.87M	-3.88M	-4.97M	-19.6M	-41.03M	-47.7M	-39.2M	-66.42M
CapEx % of Revenue	0.04%	0.11%	0.05%	0.02%	0.02%	0.05%	0.07%	0.06%	0.04%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	463K	0	0	0	0	0	-8.56M	0	0	-10.49M
Cash from Financing+	190.28M	13.18M	80.37M	113.72M	340.77M	500.85M	576.19M	482.64M	254.46M	30.2M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-6K	0	-287K	0	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-45.68M	-97.04M	-106.66M	-74.46M	-68.41M	-202.12M	-376.27M	-479.2M	-286.15M	69.24M
FCF Margin %	-0.24%	-0.45%	-0.51%	-0.29%	-0.23%	-0.52%	-0.6%	-0.58%	-0.26%	0.04%
FCF Growth %	-86.71%	-1.12%	-0.1%	0.3%	0.08%	-1.95%	-0.86%	-0.27%	0.4%	1.24%
FCF per Share	-0.96	-1.88	-1.99	-1.29	-0.98	-2.49	-4.15	-4.87	-2.49	0.56
FCF Conversion (FCF/Net Income)	0.54x	0.77x	0.72x	0.55x	0.51x	0.79x	0.71x	0.79x	0.57x	-0.71x
Interest Paid	0	0	3.57M	7.91M	12.46M	3.3M	7.08M	8.06M	11.35M	7.9M
Taxes Paid	0	0	177K	332K	2.15M	67K	283K	549K	295K	1.31M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-1046.54%	-65.76%	-206.7%	-445.14%	-80.31%	-60.07%	-82.79%	-80.62%	-59.11%	-19.42%
Return on Invested Capital (ROIC)	-	-42.73%	-72.63%	-70.11%	-36.2%	-29.73%	-41.68%	-49.13%	-53.5%	-33.27%
Gross Margin	40.72%	37.54%	33.82%	35.55%	41.96%	47.92%	49.09%	44.37%	45.52%	60.3%
Net Margin	-36.92%	-44.12%	-64.62%	-49.74%	-41.29%	-58.76%	-75.42%	-66.79%	-40.16%	-11.22%
Debt / Equity	0.23x	0.47x	4.85x	3.84x	0.56x	0.58x	0.61x	0.63x	0.58x	0.16x
Interest Coverage	-17.07x	-181.03x	-31.81x	-10.94x	-10.88x	-14.34x	-56.37x	-58.06x	-35.31x	-20.80x
FCF Conversion	0.54x	0.77x	0.72x	0.55x	0.51x	0.79x	0.71x	0.79x	0.57x	-0.71x
Revenue Growth	19.5%	14.04%	-2.83%	22.15%	17.34%	29.33%	59.97%	31.13%	31.99%	56.75%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	240.37M	269.88M	367.21M	567.15M	797.31M	1.07B	1.69B
Product Growth	-	-	-	-	12.28%	36.06%	54.45%	40.58%	34.02%	57.70%
Licensing and other	-	-	-	-	-	-	58.34M	22.91M	14.05M	11.84M
Licensing and other Growth	-	-	-	-	-	-	-	-60.72%	-38.69%	-15.74%
Oncology products	-	-	-	-	-	-	-	-	19.3M	-
Oncology products Growth	-	-	-	-	-	-	-	-	-	-
Genetic testing services	-	-	-	-	-	-	-	-	18.3M	-
Genetic testing services Growth	-	-	-	-	-	-	-	-	-	-
Licensing And Other	-	-	-	17.29M	32.45M	23.79M	-	-	-	-
Licensing And Other Growth	-	-	-	-	87.69%	-26.67%	-	-	-	-
License And Development Services	-	-	-	-	16.38M	-	-	-	-	-
License And Development Services Growth	-	-	-	-	-	-	-	-	-	-
Other Licensing And Other	-	-	-	-	10.98M	-	-	-	-	-
Other Licensing And Other Growth	-	-	-	-	-	-	-	-	-	-
Upfront License And Constellation And Paternity Services	-	-	-	-	5.09M	-	-	-	-	-
Upfront License And Constellation And Paternity Services Growth	-	-	-	-	-	-	-	-	-	-
Panorama Nipt	-	-	-	140.93M	-	-	-	-	-	-
Panorama Nipt Growth	-	-	-	-	-	-	-	-	-	-
Hcs	-	-	-	87.17M	-	-	-	-	-	-
Hcs Growth	-	-	-	-	-	-	-	-	-	-
Other Genetic Tests	-	-	-	12.26M	-	-	-	-	-	-
Other Genetic Tests Growth	-	-	-	-	-	-	-	-	-	-
Other Product Revenues	-	-	-	6.65M	-	-	-	-	-	-
Other Product Revenues Growth	-	-	-	-	-	-	-	-	-	-
Qiagen	-	-	-	5.79M	-	-	-	-	-	-
Qiagen Growth	-	-	-	-	-	-	-	-	-	-
Constellation	-	-	-	4.84M	-	-	-	-	-	-
Constellation Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
United States	-	-	-	-	-	-	590.87M	785.85M	1.05B	1.66B
United States Growth	-	-	-	-	-	-	-	33.00%	33.31%	58.24%
Europe, Middle East, India, Africa	-	-	-	-	-	-	-	16.64M	22.81M	23.88M
Europe, Middle East, India, Africa Growth	-	-	-	-	-	-	-	-	37.09%	4.70%
Asia Pacific and Other	-	-	-	-	-	-	10.14M	14.03M	7.22M	8.66M
Asia Pacific and Other Growth	-	-	-	-	-	-	-	38.37%	-48.56%	20.04%
Americas, excluding U.S.	-	-	-	-	-	-	4.05M	3.71M	4.91M	6.62M
Americas, excluding U.S. Growth	-	-	-	-	-	-	-	-8.45%	32.47%	34.88%
Europe, Middle East, India, and Africa	-	-	-	-	-	-	20.43M	-	-	-
Europe, Middle East, India, and Africa Growth	-	-	-	-	-	-	-	-	-	-
U	164.95M	193.05M	186.85M	225.93M	260.85M	365.66M	-	-	-	-
U Growth	-	17.04%	-3.22%	20.92%	15.45%	40.18%	-	-	-	-
Europe Middle East India And Africa	15.44M	14.26M	14M	20.87M	15.43M	14.33M	-	-	-	-
Europe Middle East India And Africa Growth	-	-7.65%	-1.81%	49.06%	-26.03%	-7.14%	-	-	-	-
Other Geographic Areas	-	-	-	7.38M	22.83M	7.54M	-	-	-	-
Other Geographic Areas Growth	-	-	-	-	209.14%	-66.96%	-	-	-	-
Americas Excluding Us	4.55M	2.56M	3.03M	3.47M	3.22M	3.47M	-	-	-	-
Americas Excluding Us Growth	-	-43.72%	18.19%	14.66%	-7.32%	7.80%	-	-	-	-
X	5.41M	7.2M	7.07M	-	-	-	-	-	-	-
X Growth	-	33.03%	-1.89%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Natera, Inc. (NTRA) reported $2.12B in revenue for fiscal year 2024. This represents a 14754% increase from $14.3M in 2012.

Natera, Inc. (NTRA) grew revenue by 56.7% over the past year. This is strong growth.

Natera, Inc. (NTRA) reported a net loss of $309.2M for fiscal year 2024.

Dividend & Returns

Natera, Inc. (NTRA) has a return on equity (ROE) of -19.4%. Negative ROE indicates the company is unprofitable.

Natera, Inc. (NTRA) generated $93.6M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Natera, Inc. (NTRA) 10-Year Financial Performance & Capital Metrics

NTRA • • Industrial / General

HealthcareDiagnostics & ResearchMolecular Diagnostics & Genetic TestingReproductive & Prenatal Genetics

Revenue $1.7B +56.7%
EBITDA -$191M +53.1%
Net Income -$190M +56.2%
EPS (Diluted) -1.53 +59.5%
Gross Margin 60.3% +32.5%
EBITDA Margin -11.28% +70.1%
Operating Margin -13.1% +68.2%
Net Margin -11.22% +72.1%
ROE -19.42% +67.1%
ROIC -33.27% +37.8%
Debt/Equity 0.16 -72.9%
Interest Coverage -20.80 +41.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 82 (top 18%)
✓Strong 5Y sales CAGR of 41.2%
✓Efficient asset utilization: 1.0x turnover

✗Weaknesses

✗Expensive at 25.1x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y26.69%

5Y41.2%

3Y39.47%

TTM38.17%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-44.02%

EPS CAGR

10Y-

5Y-

3Y-

TTM-29.38%

ROCE

10Y Avg-55.78%

5Y Avg-40.29%

3Y Avg-36.62%

Latest-18.14%

Peer Comparison

Reproductive & Prenatal Genetics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
SERASera Prognostics, Inc.	132.45M	3.52	-3.56	-74.84%	-343.43%	-39.7%		0.02
NTRANatera, Inc.	33.52B	240.34	-157.09	56.75%	-14.61%	-24.69%	0.21%	0.16

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	190.35M	217.07M	210.94M	257.65M	302.33M	391M	625.49M	820.22M	1.08B	1.7B
Revenue Growth %	0.2%	0.14%	-0.03%	0.22%	0.17%	0.29%	0.6%	0.31%	0.32%	0.57%
Cost of Goods Sold+	112.84M	135.57M	139.6M	166.06M	175.47M	203.62M	318.42M	456.26M	589.83M	673.75M
COGS % of Revenue	0.59%	0.62%	0.66%	0.64%	0.58%	0.52%	0.51%	0.56%	0.54%	0.4%
Gross Profit+	77.51M	81.5M	71.34M	91.6M	126.86M	187.38M	307.07M	363.97M	492.74M	1.02B
Gross Margin %	0.41%	0.38%	0.34%	0.36%	0.42%	0.48%	0.49%	0.44%	0.46%	0.6%
Gross Profit Growth %	-0.04%	0.05%	-0.12%	0.28%	0.38%	0.48%	0.64%	0.19%	0.35%	1.08%
Operating Expenses+	137.35M	177.99M	205.37M	206.23M	243.15M	403.66M	775.24M	905.01M	938.99M	1.25B
OpEx % of Revenue	0.72%	0.82%	0.97%	0.8%	0.8%	1.03%	1.24%	1.1%	0.87%	0.73%
Selling, General & Admin	109.64M	136.13M	155.31M	154.87M	206.18M	303.63M	511.03M	588.59M	618.31M	841.31M
SG&A % of Revenue	0.58%	0.63%	0.74%	0.6%	0.68%	0.78%	0.82%	0.72%	0.57%	0.5%
Research & Development	27.71M	41.86M	50.06M	51.35M	51.36M	100.03M	264.21M	316.42M	320.68M	404.14M
R&D % of Revenue	0.15%	0.19%	0.24%	0.2%	0.17%	0.26%	0.42%	0.39%	0.3%	0.24%
Other Operating Expenses	0	0	0	0	-14.39M	0	0	0	0	0
Operating Income+	-59.84M	-96.49M	-134.03M	-114.63M	-116.29M	-216.28M	-468.17M	-541.04M	-446.25M	-222.29M
Operating Margin %	-0.31%	-0.44%	-0.64%	-0.44%	-0.38%	-0.55%	-0.75%	-0.66%	-0.41%	-0.13%
Operating Income Growth %	-90.98%	-0.61%	-0.39%	0.14%	-0.01%	-0.86%	-1.16%	-0.16%	0.18%	0.5%
EBITDA+	-54.3M	-90.31M	-126.88M	-107.13M	-108.56M	-207.66M	-456.92M	-510.57M	-407.63M	-191.33M
EBITDA Margin %	-0.29%	-0.42%	-0.6%	-0.42%	-0.36%	-0.53%	-0.73%	-0.62%	-0.38%	-0.11%
EBITDA Growth %	-10.34%	-0.66%	-0.4%	0.16%	-0.01%	-0.91%	-1.2%	-0.12%	0.2%	0.53%
D&A (Non-Cash Add-back)	5.54M	6.18M	7.14M	7.5M	7.73M	8.61M	11.25M	30.47M	38.62M	30.97M
EBIT	-66.77M	-99.65M	-132.96M	-114.63M	-112.14M	-214.56M	-462.79M	-537.5M	-421.89M	-179.05M
Net Interest Income+	-2.54M	865K	-1.83M	-13.21M	-6.54M	-7.52M	-2.92M	-5.78M	11.71M	32.56M
Interest Income	964K	1.4M	2.38M	0	4.15M	7.56M	5.38M	3.54M	24.35M	43.25M
Interest Expense	3.5M	533K	4.21M	10.48M	10.69M	15.08M	8.3M	9.32M	12.64M	10.69M
Other Income/Expense	-10.44M	865K	-1.83M	-13.21M	-6.54M	-13.37M	-2.92M	-5.78M	11.71M	32.56M
Pretax Income+	-70.28M	-95.62M	-135.86M	-127.83M	-122.83M	-229.65M	-471.1M	-546.82M	-434.53M	-189.73M
Pretax Margin %	-0.37%	-0.44%	-0.64%	-0.5%	-0.41%	-0.59%	-0.75%	-0.67%	-0.4%	-0.11%
Income Tax+	0	142K	454K	321K	2M	98K	618K	978K	271K	695K
Effective Tax Rate %	1%	1%	1%	1%	1.02%	1%	1%	1%	1%	1%
Net Income+	-70.28M	-95.77M	-136.31M	-128.15M	-124.83M	-229.74M	-471.72M	-547.8M	-434.8M	-190.43M
Net Margin %	-0.37%	-0.44%	-0.65%	-0.5%	-0.41%	-0.59%	-0.75%	-0.67%	-0.4%	-0.11%
Net Income Growth %	-12.64%	-0.36%	-0.42%	0.06%	0.03%	-0.84%	-1.05%	-0.16%	0.21%	0.56%
Net Income (Continuing)	-70.28M	-95.77M	-137.63M	-128.15M	-124.83M	-229.74M	-471.72M	-547.8M	-434.8M	-190.43M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.47	-1.86	-2.54	-2.22	-1.79	-2.84	-5.21	-5.57	-3.78	-1.53
EPS Growth %	-9.5%	-0.27%	-0.37%	0.13%	0.19%	-0.59%	-0.83%	-0.07%	0.32%	0.6%
EPS (Basic)	-1.47	-1.86	-2.56	-2.22	-1.79	-2.84	-5.21	-5.57	-3.78	-1.53
Diluted Shares Outstanding	47.69M	51.58M	53.6M	57.85M	69.56M	81.01M	90.56M	98.41M	115M	124.72M
Basic Shares Outstanding	47.65M	51.45M	53.31M	57.73M	69.56M	81.01M	90.56M	98.41M	115M	124.72M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	250.73M	174.12M	180.63M	240.52M	523.17M	862.66M	1.09B	1.21B	1.26B	1.38B
Cash & Short-Term Investments	230.53M	146.12M	118.87M	153.87M	440.99M	737.27M	914.28M	898.39M	878.98M	968.28M
Cash Only	28.95M	15.26M	12.62M	46.41M	61.93M	48.67M	84.39M	466.09M	642.1M	945.59M
Short-Term Investments	201.59M	130.86M	106.25M	107.46M	379.06M	688.61M	829.9M	432.3M	236.88M	22.69M
Accounts Receivable	5.86M	13.4M	44.09M	62.22M	53.35M	78.56M	122.07M	244.38M	278.29M	314.17M
Days Sales Outstanding	11.24	22.52	76.29	88.15	64.41	73.34	71.24	108.75	93.83	67.58
Inventory	8.09M	6.41M	9M	13.63M	12.39M	20.03M	26.91M	35.41M	40.76M	44.74M
Days Inventory Outstanding	26.18	17.27	23.53	29.97	25.78	35.91	30.85	28.32	25.22	24.24
Other Current Assets	901K	1.09M	59K	4.6M	55K	187K	228K	33.63M	60.52M	48.63M
Total Non-Current Assets+	14.51M	36.56M	33.99M	27.65M	59.49M	69.49M	143.35M	182.66M	183.15M	284.92M
Property, Plant & Equipment	12.71M	32.29M	29.67M	24.34M	47.01M	54.75M	124.53M	164.33M	167.75M	248.19M
Fixed Asset Turnover	14.98x	6.72x	7.11x	10.59x	6.43x	7.14x	5.02x	4.99x	6.45x	6.84x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	1.8M	4.28M	4.32M	3.32M	12.48M	14.74M	18.82M	18.33M	15.4M	36.72M
Total Assets+	265.24M	210.68M	214.61M	268.17M	582.66M	932.15M	1.24B	1.39B	1.44B	1.66B
Asset Turnover	0.72x	1.03x	0.98x	0.96x	0.52x	0.42x	0.51x	0.59x	0.75x	1.02x
Asset Growth %	1.15%	-0.21%	0.02%	0.25%	1.17%	0.6%	0.33%	0.13%	0.03%	0.15%
Total Current Liabilities+	80.47M	96.42M	105.56M	113.98M	179.87M	199.05M	218.96M	310.5M	307.27M	344.05M
Accounts Payable	7.33M	11.48M	8.53M	14.59M	8.6M	8.1M	27.21M	31.15M	15M	34.92M
Days Payables Outstanding	23.72	30.9	22.3	32.06	17.9	14.51	31.19	24.92	9.28	18.92
Short-Term Debt	42.09M	49.62M	50.11M	50.15M	50.12M	50.05M	50.05M	80.35M	80.4M	80.36M
Deferred Revenue (Current)	144K	574K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	12.24M	22.39M	19.04M	22.68M	25.5M	47.74M	58.15M	62.96M	69.1M	73.39M
Current Ratio	3.12x	1.81x	1.71x	2.11x	2.91x	4.33x	4.99x	3.90x	4.10x	4.00x
Quick Ratio	3.02x	1.74x	1.63x	1.99x	2.84x	4.23x	4.87x	3.79x	3.96x	3.87x
Cash Conversion Cycle	13.7	8.89	77.52	86.05	72.29	94.73	70.9	112.16	109.77	72.9
Total Non-Current Liabilities+	0	7.79M	83.64M	122.03M	124.07M	246.86M	364.23M	378.23M	369.1M	121.27M
Long-Term Debt	0	0	73.06M	73.36M	73.66M	202.49M	280.39M	281.65M	282.94M	0
Capital Lease Obligations	0	0	0	0	26.3M	21.25M	61.04M	76.58M	67.03M	96.59M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	7.79M	10.57M	8.61M	310K	320K	1.48M	0	0	0
Total Liabilities	80.47M	104.2M	189.2M	236.01M	303.94M	445.92M	583.18M	688.73M	676.37M	465.31M
Total Debt+	42.09M	49.62M	123.18M	123.51M	155.81M	281.09M	397.23M	446.22M	441.99M	187.12M
Net Debt	13.14M	34.37M	110.56M	77.1M	93.89M	232.43M	312.85M	-19.87M	-200.1M	-758.47M
Debt / Equity	0.23x	0.47x	4.85x	3.84x	0.56x	0.58x	0.61x	0.63x	0.58x	0.16x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-17.07x	-181.03x	-31.81x	-10.94x	-10.88x	-14.34x	-56.37x	-58.06x	-35.31x	-20.80x
Total Equity+	184.76M	106.48M	25.42M	32.16M	278.71M	486.24M	653.3M	705.74M	765.33M	1.2B
Equity Growth %	2.08%	-0.42%	-0.76%	0.27%	7.67%	0.74%	0.34%	0.08%	0.08%	0.56%
Book Value per Share	3.87	2.06	0.47	0.56	4.01	6.00	7.21	7.17	6.66	9.58
Total Shareholders' Equity	184.76M	106.48M	25.42M	32.16M	278.71M	486.24M	653.3M	705.74M	765.33M	1.2B
Common Stock	5K	5K	6K	7K	8K	9K	10K	11K	11K	12K
Retained Earnings	-250.08M	-345.85M	-446.38M	-574.53M	-699.17M	-929.32M	-1.39B	-1.94B	-2.38B	-2.57B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.42M	-725K	-766K	-552K	919K	4.26M	-2.29M	-16.36M	-3.08M	-344K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-37.83M	-74.05M	-97.83M	-70.58M	-63.44M	-182.51M	-335.24M	-431.5M	-246.96M	135.66M
Operating CF Margin %	-0.2%	-0.34%	-0.46%	-0.27%	-0.21%	-0.47%	-0.54%	-0.53%	-0.23%	0.08%
Operating CF Growth %	-4.61%	-0.96%	-0.32%	0.28%	0.1%	-1.88%	-0.84%	-0.29%	0.43%	1.55%
Net Income	-70.28M	-100.33M	-137.63M	-128.15M	-124.83M	-229.74M	-471.72M	-547.8M	-434.8M	-190.43M
Depreciation & Amortization	5.54M	6.18M	7.14M	7.5M	7.73M	8.61M	11.25M	16.7M	24.1M	30.97M
Stock-Based Compensation	7.33M	10.6M	11.4M	14.2M	28.62M	50.17M	115.22M	152.38M	191.81M	274.43M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	10.23M	7.16M	1.65M	8.72M	-2.17M	27.58M	55.61M	30.36M	19.89M	18.55M
Working Capital Changes	9.35M	2.34M	19.61M	27.16M	27.2M	-39.13M	-45.6M	-83.15M	-47.95M	2.14M
Change in Receivables	-450K	-3.96M	6.32M	-18.09M	2.42M	-25.83M	-43.51M	-122.31M	-33.9M	-35.88M
Change in Inventory	2.93M	-431K	-3.09M	-4.9M	917K	-7.47M	-6.88M	-8.5M	-5.35M	-3.98M
Change in Payables	1.35M	1.26M	217K	3.78M	-6.26M	-118K	19.22M	5.46M	-15.46M	13.21M
Cash from Investing+	-210.68M	47.03M	13.78M	-5.16M	-266.35M	-331.46M	-205.19M	330.34M	168.5M	137.62M
Capital Expenditures	-7.85M	-23.14M	-9.87M	-3.88M	-4.97M	-19.6M	-41.03M	-47.7M	-39.2M	-66.42M
CapEx % of Revenue	0.04%	0.11%	0.05%	0.02%	0.02%	0.05%	0.07%	0.06%	0.04%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	463K	0	0	0	0	0	-8.56M	0	0	-10.49M
Cash from Financing+	190.28M	13.18M	80.37M	113.72M	340.77M	500.85M	576.19M	482.64M	254.46M	30.2M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-6K	0	-287K	0	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-45.68M	-97.04M	-106.66M	-74.46M	-68.41M	-202.12M	-376.27M	-479.2M	-286.15M	69.24M
FCF Margin %	-0.24%	-0.45%	-0.51%	-0.29%	-0.23%	-0.52%	-0.6%	-0.58%	-0.26%	0.04%
FCF Growth %	-86.71%	-1.12%	-0.1%	0.3%	0.08%	-1.95%	-0.86%	-0.27%	0.4%	1.24%
FCF per Share	-0.96	-1.88	-1.99	-1.29	-0.98	-2.49	-4.15	-4.87	-2.49	0.56
FCF Conversion (FCF/Net Income)	0.54x	0.77x	0.72x	0.55x	0.51x	0.79x	0.71x	0.79x	0.57x	-0.71x
Interest Paid	0	0	3.57M	7.91M	12.46M	3.3M	7.08M	8.06M	11.35M	7.9M
Taxes Paid	0	0	177K	332K	2.15M	67K	283K	549K	295K	1.31M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-1046.54%	-65.76%	-206.7%	-445.14%	-80.31%	-60.07%	-82.79%	-80.62%	-59.11%	-19.42%
Return on Invested Capital (ROIC)	-	-42.73%	-72.63%	-70.11%	-36.2%	-29.73%	-41.68%	-49.13%	-53.5%	-33.27%
Gross Margin	40.72%	37.54%	33.82%	35.55%	41.96%	47.92%	49.09%	44.37%	45.52%	60.3%
Net Margin	-36.92%	-44.12%	-64.62%	-49.74%	-41.29%	-58.76%	-75.42%	-66.79%	-40.16%	-11.22%
Debt / Equity	0.23x	0.47x	4.85x	3.84x	0.56x	0.58x	0.61x	0.63x	0.58x	0.16x
Interest Coverage	-17.07x	-181.03x	-31.81x	-10.94x	-10.88x	-14.34x	-56.37x	-58.06x	-35.31x	-20.80x
FCF Conversion	0.54x	0.77x	0.72x	0.55x	0.51x	0.79x	0.71x	0.79x	0.57x	-0.71x
Revenue Growth	19.5%	14.04%	-2.83%	22.15%	17.34%	29.33%	59.97%	31.13%	31.99%	56.75%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	240.37M	269.88M	367.21M	567.15M	797.31M	1.07B	1.69B
Product Growth	-	-	-	-	12.28%	36.06%	54.45%	40.58%	34.02%	57.70%
Licensing and other	-	-	-	-	-	-	58.34M	22.91M	14.05M	11.84M
Licensing and other Growth	-	-	-	-	-	-	-	-60.72%	-38.69%	-15.74%
Oncology products	-	-	-	-	-	-	-	-	19.3M	-
Oncology products Growth	-	-	-	-	-	-	-	-	-	-
Genetic testing services	-	-	-	-	-	-	-	-	18.3M	-
Genetic testing services Growth	-	-	-	-	-	-	-	-	-	-
Licensing And Other	-	-	-	17.29M	32.45M	23.79M	-	-	-	-
Licensing And Other Growth	-	-	-	-	87.69%	-26.67%	-	-	-	-
License And Development Services	-	-	-	-	16.38M	-	-	-	-	-
License And Development Services Growth	-	-	-	-	-	-	-	-	-	-
Other Licensing And Other	-	-	-	-	10.98M	-	-	-	-	-
Other Licensing And Other Growth	-	-	-	-	-	-	-	-	-	-
Upfront License And Constellation And Paternity Services	-	-	-	-	5.09M	-	-	-	-	-
Upfront License And Constellation And Paternity Services Growth	-	-	-	-	-	-	-	-	-	-
Panorama Nipt	-	-	-	140.93M	-	-	-	-	-	-
Panorama Nipt Growth	-	-	-	-	-	-	-	-	-	-
Hcs	-	-	-	87.17M	-	-	-	-	-	-
Hcs Growth	-	-	-	-	-	-	-	-	-	-
Other Genetic Tests	-	-	-	12.26M	-	-	-	-	-	-
Other Genetic Tests Growth	-	-	-	-	-	-	-	-	-	-
Other Product Revenues	-	-	-	6.65M	-	-	-	-	-	-
Other Product Revenues Growth	-	-	-	-	-	-	-	-	-	-
Qiagen	-	-	-	5.79M	-	-	-	-	-	-
Qiagen Growth	-	-	-	-	-	-	-	-	-	-
Constellation	-	-	-	4.84M	-	-	-	-	-	-
Constellation Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
United States	-	-	-	-	-	-	590.87M	785.85M	1.05B	1.66B
United States Growth	-	-	-	-	-	-	-	33.00%	33.31%	58.24%
Europe, Middle East, India, Africa	-	-	-	-	-	-	-	16.64M	22.81M	23.88M
Europe, Middle East, India, Africa Growth	-	-	-	-	-	-	-	-	37.09%	4.70%
Asia Pacific and Other	-	-	-	-	-	-	10.14M	14.03M	7.22M	8.66M
Asia Pacific and Other Growth	-	-	-	-	-	-	-	38.37%	-48.56%	20.04%
Americas, excluding U.S.	-	-	-	-	-	-	4.05M	3.71M	4.91M	6.62M
Americas, excluding U.S. Growth	-	-	-	-	-	-	-	-8.45%	32.47%	34.88%
Europe, Middle East, India, and Africa	-	-	-	-	-	-	20.43M	-	-	-
Europe, Middle East, India, and Africa Growth	-	-	-	-	-	-	-	-	-	-
U	164.95M	193.05M	186.85M	225.93M	260.85M	365.66M	-	-	-	-
U Growth	-	17.04%	-3.22%	20.92%	15.45%	40.18%	-	-	-	-
Europe Middle East India And Africa	15.44M	14.26M	14M	20.87M	15.43M	14.33M	-	-	-	-
Europe Middle East India And Africa Growth	-	-7.65%	-1.81%	49.06%	-26.03%	-7.14%	-	-	-	-
Other Geographic Areas	-	-	-	7.38M	22.83M	7.54M	-	-	-	-
Other Geographic Areas Growth	-	-	-	-	209.14%	-66.96%	-	-	-	-
Americas Excluding Us	4.55M	2.56M	3.03M	3.47M	3.22M	3.47M	-	-	-	-
Americas Excluding Us Growth	-	-43.72%	18.19%	14.66%	-7.32%	7.80%	-	-	-	-
X	5.41M	7.2M	7.07M	-	-	-	-	-	-	-
X Growth	-	33.03%	-1.89%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Natera, Inc. (NTRA) reported $2.12B in revenue for fiscal year 2024. This represents a 14754% increase from $14.3M in 2012.

Natera, Inc. (NTRA) grew revenue by 56.7% over the past year. This is strong growth.

Natera, Inc. (NTRA) reported a net loss of $309.2M for fiscal year 2024.

Dividend & Returns

Natera, Inc. (NTRA) has a return on equity (ROE) of -19.4%. Negative ROE indicates the company is unprofitable.

Natera, Inc. (NTRA) generated $93.6M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.